Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Yuka TakahashiHiroshi NomotoHiroki YokoyamaYoshinari TakanoSo NagaiAtsushi TsuzukiKyu Yong ChoAika MiyaHiraku KamedaJun TakeuchiShinji TanedaYoshio KuriharaTatsuya AtsumiAkinobu NakamuraHideaki Miyoshinull nullPublished in: Diabetes, obesity & metabolism (2023)
Once-weekly semaglutide administration improved glycaemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite glucagon-like receptor-1 receptor agonist treatment.